7 results about "Diosmetin" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition for resisting doxorubicin cardiotoxicity and a preparation method, application and a preparation thereof. The invention provides a composition capable of resisting doxorubicin cardiotoxicity, the composition comprises diosmetin and loureirin B, the diosmetin and the loureirin B can be extracted through natural plants, the raw materials are low in cost and easy to obtain, and clinical popularization and application are facilitated. The cell experiment research finds that the combined administration of diosmetin and loureirin B can significantly improve the survival rate of adriamycin-damaged myocardial cells and significantly reduce the active oxygen level and positive cell rate, and verifies the synergistic interaction of diosmetin and loureirin B in resisting adriamycin cardiotoxicity.

A method for extracting flavonoid components in Dracocephalum moldavica L., comprising the following steps: mixing Dracocephalum moldavica L. and an alkaline solution for heating extraction; under the condition that the pH value is 1-3, mixing an obtained extract solution with acid for precipitation; dissolving an obtained precipitated extract and then carrying out preparative liquid chromatography separation; and respectively concentrating obtained Fr1-Fr6 fractions until the fractions are dry, so as to sequentially obtain luteolin-7-O-β-D-glucuronide, apigenin-7-O-β-D-glucuronide, diosmetin-7-O-β-D-glucuronide, tilianin, acacetin-7-O-glucuronide, and acacetin.

This pharmaceutical composition for chronic venous disease includes one or more diosmetin compounds selected from the group consisting of a diosmetin-7-glucoside-cyclodextrin inclusion compound and a diosmetin glycosyltransferase of formula (1). The pharmaceutical composition can be used for the prevention or treatment of chronic venous disease.

The utility model discloses diosmetin purification equipment which comprises a machine box, the machine box is divided into a spraying chamber and an evaporation chamber through a built-in partition plate, a shock excitation disc is arranged in an opening in the top of the spraying chamber, an outlet in the bottom face of the shock excitation disc is located in a disc opening of a filter disc, the bottom of the filter disc is connected with an inlet of a control valve through a bent pipe, and a valve body of the control valve is embedded in the partition plate. An outlet of the control valve is located above the evaporation dish, the evaporation dish is placed on a heater on the bottom surface of the evaporation chamber, an exhaust pipe in the evaporation chamber is communicated into an alcohol barrel, the alcohol barrel is connected with the input end of a circulating pump, and the output end of the circulating pump is connected with a shower located above the shock excitation disc; according to the equipment, coarse diosmetin can be dissolved in alcohol through the cooperation of the excitation disc and the shower head, the alcohol is filtered through the filter disc and then conveyed into the evaporation dish in the evaporation chamber to be evaporated and crystallized, the evaporated alcohol can flow back into the alcohol barrel to be repeatedly sprayed, and the equipment has the characteristics of energy conservation, emission reduction, easiness in operation and low pollution.

The application of a natural small molecule compound in the preparation of a drug for treating a disease related to CSF1R function loss belongs to the technical field of medicine. The natural small molecule compound Diosmetin-7-O-beta-D-glucopyranoside (DDG) can effectively improve the disease phenotype of a CSF1R function loss model mouse by up-regulating the transcription and protein expression of CSF1R in microglia through enhancing the activity of a super-enhancer FIRE in the second intron of the CSF1R gene. The drug can be prepared into injection preparations, oral preparations, spray preparations, ointment preparations or patches, and provides a natural small molecule treatment scheme for diseases related to the weakening / loss of CSF1R content or function, and has a wide clinical application prospect.

The invention belongs to the technical field of medicines, and discloses application of diosmetin shown as a formula (I) and pharmacodynamically acceptable salts thereof in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. In a mouse experimental autoimmune encephalomyelitis model, diosmetin shows a good treatment effect, and can effectively prevent and treat pathological changes and disease progression, relieve disease severity and inhibit LPS-stimulated microglial BV2 cells from releasing an inflammatory mediator, thereby providing a new drug and a new structure for clinical treatment.

The invention belongs to the technical field of traditional Chinese medicine modernization, and particularly relates to a composition for preventing or treating chronic atrophic gastritis, application and a product. The composition for preventing or treating the chronic atrophic gastritis, provided by the invention, consists of isorhoifolin, ginsenoside Re, naringin, ginsenoside Rc and diosmetin. The composition provided by the invention can inhibit an inflammatory cell PI3K / AKT pathway, activate a gastric mucosa epithelial cell MAPK pathway, inhibit expression of inflammatory factors such as IL-6 and TNF-alpha and promote GAST gastrin gene expression, so that inflammation is inhibited, gastrin secretion is promoted, gastric motility is enhanced, gastric mucosa epithelial cell repair is promoted, and the effect of preventing or treating chronic atrophic gastritis is achieved. In addition, the components of the composition disclosed by the invention are rich in araliaceae and rutaceae medicinal and edible products and small in toxic and side effects, and the composition shows a good application prospect in preparation of medicines for preventing or treating chronic atrophic gastritis.